#110 – A Bone to Pick: Biofilm Busters for Prosthetic Joint Infections
Jan 24, 2025
auto_awesome
Nico Cortes-Penfield, an expert in infectious diseases, Jessica Seidelman, a hospital epidemiologist, and Kerry LaPlante, a pioneering pharmacist, delve into the complexities of biofilms in prosthetic joint infections. They discuss the challenges in eradicating biofilms with antibiotics and explore innovative non-pharmacologic strategies like bacteriophages and electromagnetism. Their insights shed light on the need for tailored treatment approaches and the ongoing evolution of testing methods to combat these persistent infections effectively.
Biofilms significantly complicate the treatment of prosthetic joint infections by providing powerful resistance against antibiotics and host defenses.
Current antibiotic therapies often fail to completely eradicate biofilm-associated infections, highlighting the need for surgical interventions in severe cases.
Innovative non-pharmacologic approaches, like bacteriophages and electromagnetic forces, are being researched to improve outcomes in biofilm-related infections.
Deep dives
Understanding Biofilm Structure
A biofilm is a complex structure formed by bacterial cells embedded in a matrix of extracellular polymeric substances (EPS) that can include polysaccharides, proteins, and DNA. This matrix provides a protective environment, allowing bacteria to thrive and resist treatment. Unlike free-floating bacteria, those in a biofilm exhibit unique behaviors, including altered gene expression and a strong adhesion to surfaces, making them difficult to remove or treat with antibiotics. The resilient nature of biofilms significantly contributes to challenges in treating infections, as traditional antibiotics often fail to penetrate effectively.
Pathophysiology of Prosthetic Joint Infections
Biofilms play a crucial role in the development of prosthetic joint infections, beginning when bacteria attach to the surface of an implant and form a protective biofilm. Once established, the biofilm shields bacteria from both the host immune response and antibiotic treatment, complicating efforts to achieve infection resolution. The persistence of bacteria within biofilms often leads to recurrent infections or systemic symptoms, necessitating surgical intervention for definitive treatment. Understanding biofilms is essential for developing new prevention and treatment strategies for these infections.
Impact of Biofilm Stages on Antibiotic Treatment
The development of biofilms can be categorized into distinct stages, each influencing antibiotic effectiveness. Antibiotics tend to be most effective during the initial attachment stage, while mature biofilms present substantial resistance to conventional treatments. Studies indicate that while certain antibiotics, such as daptomycin, may show reduced biofilm mass, complete eradication has not been achieved with any currently tested therapies. This underscores the necessity for surgical intervention in many cases of prosthetic joint infections, as antibiotics alone are often insufficient.
Challenges of Addressing Fungal Biofilms
Fungi, such as Candida species, also form biofilms that are notably difficult to treat, with existing antifungal therapies proving ineffective against these structures. Evidence suggests that infections caused by fungal biofilms frequently require the removal of infected hardware for successful treatment, as failure rates with hardware retention are alarmingly high. Moreover, the complex architecture and biology of fungal biofilms complicate efforts to develop effective therapies, highlighting the urgent need for research focused on antifungal biofilm interventions. The challenge posed by fungal infections represents an important area for further investigation, given their rising incidence in clinical settings.
Future Approaches and Research Needs
Advancements in various therapeutic strategies, including the use of bacteriophages, enzymes, and innovative mechanical approaches, are being explored to combat biofilm-related infections. Techniques such as electromagnetic forces and ultrasonic debridement show promise, yet standardized and greater clinical research is essential for establishing their efficacy. In addition, the implementation of biofilm-specific susceptibility testing remains an important research priority, potentially allowing for more tailored treatments for infections caused by biofilm-forming bacteria. A multidisciplinary approach that brings together researchers, clinicians, and pharmacists is imperative to advance understanding and optimize management of biofilm-related infections.
Drs. Nico Cortes-Penfield (@Cortes-Penfield), Kerry LaPlante (@Kerry_LaPlante), Jessica Seidelman (@JessieLSeidel) join Dr. Julie Ann Justo (@julie_justo) to discuss the pesky slime that is biofilm in periprosthetic joint infections. They review biofilm composition & development, have an honest discussion about whether antibiotics can ever really eradicate it, and provide updates on the promising non-pharmacologic strategies on the horizon (bacteriophages, electromagnetism, & more).
Review on Staphylococcal biofilm development: Schilcher K, Horswill AR. 2020 Aug 12;84(3):e00026-19. doi: 10.1128/MMBR.00026-19. PMID: 32792334.
Antibiotics can fail to kill biofilm cells even if they penetrate the biofilm: Singh R, et al. Pathog Dis. 2016 Aug;74(6):ftw056. doi: 10.1093/femspd/ftw056. Epub 2016 Jul 7. PMID: 27402781.
Clinical and genetic risk factors for biofilm-forming Staphylococcus aureus: Luther MK, et al. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02252-17. doi: 10.1128/AAC.02252-17. PMID: 29530854.
Meta-analysis showing poor clinical outcomes with debridement, antibiotics, and implant retention (DAIR): Kunutsor SK, et al. J Infect. 2018 Dec;77(6):479-488. doi: 10.1016/j.jinf.2018.08.017. PMID: 30205122.
Thieme L, et al. MBEC versus MBIC: the lack of differentiation between biofilm reducing and inhibitory effects as a current problem in biofilm methodology. Biol Proced Online 21, 18 (2019). https://doi.org/10.1186/s12575-019-0106-0.
Ongoing trial investigating use of MBEC in the treatment of PJIs: Tillander JAN, et al. BMJ Open. 2022 Sep 15;12(9):e058168. doi: 10.1136/bmjopen-2021-058168. PMID: 36109038.
Maale, G. Complete eradication of biofilm using low frequency electromagnetic force (EMF) and antibiotics at MIC. 34th Annual Meeting Musculoskeletal Infection Society. 2024 Aug. Abstract 1232 (see full program).
Meta-analysis on bacteriophages for biofilm: Kovacs CJ, et al. Mil Med. 2024 May 18;189(5-6):e1294-e1302. doi: 10.1093/milmed/usad385. PMID: 37847552.
Berking BB, et al. Biofilm disruption from within: light-activated molecular drill-functionalized polymersomes bridge the gap between membrane damage and quorum sensing-mediated cell death. ACS Biomater Sci Eng. 2024 Sep 9;10(9):5881-5891. doi: 10.1021/acsbiomaterials.4c01177. PMID: 39176452.
Aboelnaga N, et al. Deciphering the dynamics of methicillin-resistant Staphylococcus aureus biofilm formation: from molecular signaling to nanotherapeutic advances. Cell Commun Signal. 2024 Mar 22;22(1):188. doi: 10.1186/s12964-024-01511-2. PMID: 38519959.
Conway J, et al. Phase 1 study of the pharmacokinetics and clinical proof-of-concept activity of a biofilm-disrupting human monoclonal antibody in patients with chronic prosthetic joint infection of the knee or hip. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0065524. doi: 10.1128/aac.00655-24. PMID: 39012102.
Mulpur P, et al. Efficacy of intrawound vancomycin in prevention of periprosthetic joint infection after primary total knee arthroplasty: a prospective double-blinded randomized control trial. J Arthroplasty. 2024 Jun;39(6):1569-1576. doi: 10.1016/j.arth.2024.01.003. PMID: 38749600.
Dong Y, et al. Synergy of ultrasound microbubbles and vancomycin against Staphylococcus epidermidis biofilm. J Antimicrob Chemother. 2013 Apr;68(4):816-26. doi: 10.1093/jac/dks490. PMID: 23248238.
Miltenberg B, et al. Intraosseous Regional Administration of Antibiotic Prophylaxis for Total Knee Arthroplasty: A Systematic Review. J Arthroplasty. 2023 Apr;38(4):769-774. doi: 10.1016/j.arth.2022.10.023. PMID: 36280158.
Viswanathan VK, et al. Intraosseous regional antibiotic prophylaxis in total joint arthroplasty (TJA): Systematic review and meta-analysis. J Clin Orthop Trauma. 2024 Oct 3;57:102553. doi: 10.1016/j.jcot.2024.102553. PMID: 39435324.
SOLARIO trial: Dudareva M, et al. The European Bone and Joint Infection Society Meeting, 2024 Sept.
Fehring TK, et al. Does treatment at a specialized prosthetic joint infection center improve the rate of reimplantation. J Arthroplasty. 2023 Jun;38(6S):S314-7. PMID 37004968.
